Results 11 to 20 of about 1,253,570 (258)

Genetic Variation at the Sulfonylurea Receptor, Type 2 Diabetes, and Coronary Heart Disease [PDF]

Diabetes, 2017
Despite widespread clinical use in the treatment of type 2 diabetes, the impact of sulfonylurea therapy on cardiovascular outcomes remains uncertain.
Amit V Khera, Pradeep Natarajan, Jose C Florez   +2 more
exaly   +3 more sources

Successful Use of a GLP-1 Receptor Agonist as Add-on Therapy to Sulfonylurea in the Treatment of KCNJ11 Neonatal Diabetes [PDF]

European Journal of Case Reports in Internal Medicine, 2021
Sulfonylurea monotherapy is the standard treatment for patients with the most common form of permanent neonatal diabetes, KCNJ11 neonatal diabetes, but it is not always sufficient.
Morten Hindsø, Christoffer Martinussen, Maria Saur Svane, Simon Veedfald, Birthe Gade-Rasmussen, Torben Hansen, Sten Madsbad   +6 more
doaj   +2 more sources

Effective Treatment With Oral Sulfonylureas in Patients With Diabetes Due to Sulfonylurea Receptor 1 (SUR1) Mutations [PDF]

Diabetes Care, 2008
OBJECTIVE—Neonatal diabetes can result from mutations in the Kir6.2 or sulfonylurea receptor 1 (SUR1) subunits of the ATP-sensitive K+ channel. Transfer from insulin to oral sulfonylureas in patients with neonatal diabetes due to Kir6.2 mutations is well described, but less is known about changing therapy in patients with SUR1 mutations.
Rafiq, Meena, Flanagan, Sarah E., Patch, Ann Marie, Shields, Beverley M., Ellard, Sian, Hattersley, Andrew T., Batra, Chandar, Bruining, Jan, Carson, Dennis, Codner, Ethel, Cummings, Elizabeth, Curran, Jacqueline, Davis, Elizabeth, Deiss, Dorothee, Herr, Mathias, Hussain, Khalid, Legault, Laurent, Malecki, Maciek, Paskova, Magdalena, Pearson, Ewan, Rodda, Christine, Rothenbuhler, Anya, Sanchez, Juan, Shield, Julian, Stanca, Ràcealà Motoc, Van Der Meulen, John   +25 more
openaire   +6 more sources

Sulfonylurea Receptor-1: A Novel Biomarker for Cerebral Edema in Severe Traumatic Brain Injury. [PDF]

Crit Care Med, 2017
OBJECTIVES: Cerebral edema is a key poor prognosticator in traumatic brain injury. There are no biomarkers identifying patients at-risk, or guiding mechanistically-precise therapies.
Jha RM, Puccio AM, Chou SH, Chang CH, Wallisch JS, Molyneaux BJ, Zusman BE, Shutter LA, Poloyac SM, Janesko-Feldman KL, Okonkwo DO, Kochanek PM.   +11 more
europepmc   +2 more sources

Dulaglutide versus empagliflozin as add-on therapy to metformin and sulfonylurea in type 2 diabetes: a randomized pilot study with exploratory metabolomic and microbiome analyses [PDF]

Frontiers in Endocrinology
In patients with type 2 diabetes mellitus (T2DM) inadequately controlled with metformin and sulfonylurea, evidence directly comparing glucagon-like peptide-1 receptor agonists and sodium–glucose cotransporter 2 inhibitors as add-on therapy is limited ...
Ji Eun Jun, Da-Hee Oh, Da-Hee Oh, In-Kyung Jeong, Hyun Jin Ryu, You-Cheol Hwang, Kyu Jeung Ahn, Ho Yeon Chung, Kwang Pyo Kim   +8 more
doaj   +2 more sources

Role of Sulfonylurea Receptor 1 and Glibenclamide in Traumatic Brain Injury: A Review of the Evidence. [PDF]

Int J Mol Sci, 2020
Cerebral edema and contusion expansion are major determinants of morbidity and mortality after TBI. Current treatment options are reactive, suboptimal and associated with significant side effects.
Jha RM, Bell J, Citerio G, Hemphill JC, Kimberly WT, Narayan RK, Sahuquillo J, Sheth KN, Simard JM.   +8 more
europepmc   +2 more sources

Overexpression of a Short Sulfonylurea Splice Variant Increases Cardiac Glucose Uptake and Uncouples Mitochondria by Regulating ROMK Activity

Life, 2023
The mitochondrial splice variant of the sulfonylurea receptor (SUR2A-55) is associated with protection from myocardial ischemia-reperfusion (IR) injury, increased mitochondrial ATP sensitive K+ channel activity (mitoKATP) and altered glucose metabolism ...
Sarah K. El-Meanawy, Holly Dooge, Allison C. Wexler, Anna C. Kosmach, Lara Serban, Elizabeth A. Santos, Francisco J. Alvarado, Timothy A. Hacker, Mohun Ramratnam   +8 more
doaj   +1 more source

Pharmacological Profiling of K_ATP Channel Modulators: An Outlook for New Treatment Opportunities for Migraine

Pharmaceuticals, 2023
Migraine is a highly disabling pain disorder with huge socioeconomic and personal costs. It is genetically heterogenous leading to variability in response to current treatments and frequent lack of response. Thus, new treatment strategies are needed.
Tino Dyhring, Inger Jansen-Olesen, Palle Christophersen, Jes Olesen   +3 more
doaj   +1 more source

Transient neonatal diabetes mellitus caused by a gene mutation [PDF]

Korean Journal of Pediatrics, 2011
Transient neonatal diabetes mellitus (TNDM) is a rare form of diabetes mellitus that presents within the first 6 months of life with remission in infancy or early childhood.
Jung Hyun Kong, June Bum Kim
doaj   +1 more source

Risk of new-onset prostate cancer for Metformin versus Sulfonylurea use in Type 2 Diabetes Mellitus: A propensity score-matched study [PDF]

, 2022
The aim of this study was to compare the risks of new-onset prostate cancer between metformin and sulfonylurea users with type 2 diabetes mellitus (T2DM).
Liu, Xuejin, Hui, Kyle, Liu, Tong, Wai, Abraham Ka Chung, Lee, Teddy Tai Loy, Lee, Sharen, Zhou, Jiandong, Chan, Jeffrey Shi Kai, Tse, Gary, Lee, Yan Hiu Athena, Wong, Wing Tak, Zhang, Qingpeng, Ng, Kenrick, Dee, Edward Christopher, Hui, Jeremy Man Ho   +14 more
core   +2 more sources